Navigation Links
Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says
Date:11/11/2008

More than 7,000 C. difficile Inpatients on Any One Day; Patients Dispersed Across Hospital Units

ORLANDO, Fla., Nov. 11 /PRNewswire-USNewswire/ -- The life-threatening bacterium that causes diarrhea and more serious intestinal conditions, Clostridium difficile, is sickening many more patients than previously estimated, according to a new study released today by the Association for Professionals in Infection Control and Epidemiology (APIC).

"The National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities" indicates that 13 out of every 1,000 inpatients were either infected or colonized with C. difficile. Based on this rate, it is estimated that there are at least 7,178 inpatients on any one given day in American healthcare institutions with an associated cost of $17.6 to $51.5 million. The rate is 6.5 to 20 times greater than previous incidence estimates, according to the survey, released at APIC's conference, "Clostridium difficile: A Call to Action," in Orlando, Florida.

The APIC survey, the largest, most comprehensive of its kind, presents a one-day snapshot in time of the prevalence of C. difficile infection (CDI) in American hospitals. APIC's 12,000 members collected data about all of their CDI patients on one day between May and August 2008. Survey results were collected from 12.5% of all medical facilities in the U.S. that care for virtually every type of patient, including those at acute care, cancer, cardiac, children's, long-term care and rehabilitation hospitals. A total of 1,443 patients were identified with CDI from among the 648 participating hospitals.

CDI is most frequently associated with previous antibiotic use and is most commonly contracted by the elderly and those with recent exposure to hospitals, nursing homes and other healthcare institutions. It is transmitted by hand contact with items contaminated by feces. In the last five years, a more virulent and antibiotic-resistant strain has developed which has been associated with more serious disease, treatment failures and deaths.

"This study shows that C. difficile infection is an escalating issue in our nation's healthcare facilities," said William Jarvis, MD, principal investigator of the study and president and co-founder of Jason and Jarvis Associates, a private consulting firm in healthcare epidemiology. "Clearly, preventing the development and transmission of CDI should be a top priority for every healthcare institution."

According to the survey, 54.4 percent of patients with CDI were identified within 48 hours of admission and 84.7 percent were on the medical services, meaning they were being treated for general medical conditions like diabetes, pulmonary or cardiac problems and were on wards throughout the hospital.

"Our results show that the majority of CDI patients are admitted to the hospital already infected," said APIC 2008 President Janet E. Frain, RN, CIC, CPHQ, CPHRM, Director, Integrated Services, Sutter Medical Center in Sacramento, CA. "Hospitals need to be looking for patients with severe diarrhea, and if CDI is suspected, promptly institute appropriate precautions such as gloves, gowns and separating patients, to avoid spreading the infection. Early recognition of CDI is critical so that prevention measures can be implemented."

To reduce the risk of transmission, APIC has published a "Guide to the Elimination of Clostridium difficile in Healthcare Settings." APIC recommendations include a risk assessment to identify high-risk areas for CDI within the institution; surveillance program to outline activities and procedures to provide early identification of CDI cases; adherence to CDC hand hygiene guidelines; use of contact precautions (e.g., gloves, gowns and separating CDI patients from other patients); environmental and equipment cleaning and decontamination, especially items that are close to patients such as bedrails and bedside equipment; and antimicrobial stewardship programs with focus on restriction of antibiotics associated with CDI and unnecessary antimicrobial use. APIC's evidence-based elimination guides translate CDC recommendations into practice.

"Healthcare providers must intensify efforts toward developing prevention strategies that can be consistently applied across the continuum of care," said APIC CEO Kathy L. Warye. "Control of CDI requires adequate numbers of infection preventionists and environmental services personnel, and prevention practices need to be part of everyone's job within the institution. As part of our Targeting Zero initiative, APIC will continue to call for the commitment of clinical and administrative leadership to providing adequate resources for infection prevention programs to better protect patients in our nation's healthcare facilities."

The APIC National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities will be published in the American Journal of Infection Control. For more information about the study, visit http://www.apic.org.

APIC's mission is to improve health and patient safety by reducing risks of infection and other adverse outcomes. The association's 12,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities around the globe. APIC advances its mission through education, research, collaboration, practice guidance, public policy and credentialing. Visit APIC online at http://www.apic.org


'/>"/>
SOURCE Association for Professionals in Infection Control andEpidemiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Irritable Bowel Syndrome Takes Center Stage at Yakults 17th Intestinal Flora Symposium
2. Strategies for preventing gastrointestinal complications in severely burned patients
3. Pneumatosis cystoids intestinalis after fluorouracil chemotherapy
4. A new breakthrough in timing of urgent endoscopy for gastrointestinal bleeding patients
5. Ben-Gurion University of the Negev initiates project to eliminate intestinal worms in Ethiopia
6. Intestinal Gluten Receptor Is Gateway for Celiac Disease
7. July 2008 Mayo Clinic Womens HealthSource Highlights Vitamin D, Savvy Use of Sunscreen and Gastrointestinal Upset and Celiac Disease
8. Medical check-ups for intestinal cancer are hardly used
9. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
10. Discovery of new family of genetic mutations involved in inflammatory intestinal disease
11. Protein predicts Gleevec resistance in gastrointestinal tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of ... Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities ... before the big event. The invitation-only gifting suite, held this year at the W ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to bring patients ... office. Beginning in January, Miami Dental Specialists will offer the non-metal implants as a ... office to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... INC. (NasdaqCM: PDEX) today announced financial results for its fiscal ... filed its Quarterly Report on Form 10-Q for the second ... Commission today. --> --> ... --> Net sales for the three months ended ... million from $2.8 million for the three months ended December ...
Breaking Medicine Technology: